JGC
SWTX

J. Goldman & Co’s SpringWorks Therapeutics SWTX Stock Holding History

J. Goldman & Co’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,951
Closed -$704K – 635
2025
Q1 		$704K Sell
15,951
-37,552
-70% -$1.73M 0.02% 382
2024
Q4 		$1.93M Sell
53,503
-9,733
-15% -$340K 0.05% 278
2024
Q3 		$2.03M Sell
63,236
-162,698
-72% -$6.08M 0.06% 229
2024
Q2 		$8.51M Buy
225,934
+108,806
+93% +$4.58M 0.24% 124
2024
Q1 		$5.77M Buy
+117,128
New +$5.42M 0.19% 137

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

J. Goldman & Co's SWTX Position: Q2 2025 in Review

J. Goldman & Co sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 15,951 shares — an estimated $704K sold.

J. Goldman & Co first reported a position in SWTX in Q1 2024 and held it in 5 quarters. The position peaked at $8.51M in Q2 2024. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • J. Goldman & Co reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • J. Goldman & Co sold 15,951 SpringWorks Therapeutics shares in Q2 2025, an estimated $704K.
  • J. Goldman & Co first reported a position in SpringWorks Therapeutics in Q1 2024 and held it in 5 quarters.
  • J. Goldman & Co's SpringWorks Therapeutics position peaked at $8.51M in Q2 2024.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.